Basf Se Corporation

Massachusetts Institute of Technology

Pfizer Corporation

Samir Kulkarni

Patricia Andres

Jennifer Leigh Nelson

Brian Michael Green

Matthew Richard Oberholzer

Stephen Craig Fields

Robert Steven Kania

Robert Louis Hoffman

Dafydd Rhys Owen

Jamison Bryce Tuttle

Allan Stuart Myerson

Matthew Forrest Sammons

Suman Luthra

Klimentina Dimitrova Pencheva

Anil Mahadeo Rane

Jonathan Richard Lillis

Martyn David Ticehurst

Matthew Nathan O'Brien Laramy

Bradley Paul Sullivan

Andrew John Thiel

Padmavani Bezawada

Rohit Jaini

Emma Louise Hawking

Solid forms of L-glufosinate materials, including crystalline L-glufosinate ammonium, are described.

Methods for the purification of L-glufosinate

The invention relates to compounds of formula I wherein R, Rand - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

Compounds and methods for the treatment of COVID-19

Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate. In some embodiments, a portion of the glutamate in the starting composition may be separated from the L-glufosinate using a crystallization step. Solid forms of L-glufosinate materials, including crystalline L-glufosinate ammonium, are also described.

Aspects of the disclosure relate to methods and compositions of altering a solution through the use of readily retrievable agents (e.g., a nanoparticle) having one or more functional groups configured to undergo a solvation interaction with a component of the solution. Compositions, systems, and methods for crystallizing organic and inorganic compounds from solutions using nanoparticles surface coated with functional groups that create a supersaturated state in the solution and reversal thereof. Compositions, systems, and methods for purifying water or active pharmaceutical ingredients. Compositions, systems, and methods for increasing the solubility of a solution and reversal of the same. Compositions, systems, and methods for decreasing the solubility of a crystallized compound and reversal of the same.

Reversible control of solution solubility using functionalized nanoparticles

Growing community of inventors

East Lyme, CT, United States of America

Samir Kulkarni